Liver and Biliary Pathology — MCQs

Liver and Biliary Pathology Indian Medical PG Practice Questions and MCQs

Question 281: Bile ductopenia is seen in which of the following conditions?

A. Graft-versus-host disease (GVHD) (Correct Answer)
B. Alcoholic hepatitis
C. Autoimmune hepatitis
D. Cirrhosis

Explanation: **Explanation:** **Bile ductopenia** refers to the progressive loss or disappearance of intrahepatic bile ducts. It is defined histologically as the absence of bile ducts in more than 50% of the portal tracts in a liver biopsy specimen [1]. **Why Option A is Correct:** In **Graft-versus-host disease (GVHD)**, specifically the chronic form following hematopoietic stem cell transplantation, donor T-cells recognize the host's biliary epithelial cells as foreign. This leads to direct immunological destruction of the small bile ducts (vanishing bile duct syndrome), resulting in cholestasis and ductopenia. **Why Other Options are Incorrect:** * **B. Alcoholic hepatitis:** Characterized by hepatocyte swelling (ballooning), Mallory-Denk bodies, and neutrophil infiltration. It does not typically involve the destruction of bile ducts. * **C. Autoimmune hepatitis:** Primarily involves "interface hepatitis" (lymphoplasmacytic infiltrate at the limiting plate) and hepatocyte necrosis. While it can overlap with biliary diseases, ductopenia is not a hallmark feature. * **D. Cirrhosis:** This is the end-stage of various chronic liver diseases characterized by diffuse fibrosis and regenerative nodules [1]. While bile ducts may be distorted, ductopenia is not the defining pathological process. **High-Yield Clinical Pearls for NEET-PG:** * **Differential Diagnosis of Ductopenia:** Apart from GVHD, other high-yield causes include **Primary Biliary Cholangitis (PBC)**, **Primary Sclerosing Cholangitis (PSC)**, Alagille syndrome (congenital), and chronic rejection of a liver transplant [1], [2]. * **Histology Hint:** Look for "portal tracts without accompanying bile ducts" alongside the hepatic artery branches. * **Clinical Presentation:** Patients typically present with features of obstructive jaundice (itching, raised Alkaline Phosphatase, and conjugated hyperbilirubinemia). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 864-865. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 865-866.

Question 282: Hemolytic anemia is associated with which of the following types of gallstones?

A. Pigmented (Correct Answer)
B. Mixed
C. Cholesterol
D. None of the above

Explanation: **Explanation:** **1. Why Pigmented Stones are the Correct Answer:** Pigmented gallstones (specifically **Black Pigment Stones**) are primarily composed of calcium bilirubinate [3]. In conditions of **chronic hemolysis** (e.g., Hereditary Spherocytosis, Sickle Cell Anemia, Thalassemia), there is an excessive breakdown of red blood cells [1]. This leads to an increased production of unconjugated bilirubin [1]. When the liver excretes this excess bilirubin into the bile, it can precipitate with calcium to form hard, radiopaque black stones within the gallbladder [1]. **2. Why Other Options are Incorrect:** * **Cholesterol Stones:** These are the most common type of gallstone globally [2]. They form due to supersaturation of bile with cholesterol, often associated with the "4 F's": Female, Fat, Fertile, and Forty [2]. Hemolysis does not increase cholesterol levels in bile. * **Mixed Stones:** These contain a combination of cholesterol, calcium salts, and bile pigments. While they are common in patients with chronic cholecystitis, they are not the classic hallmark of a primary hemolytic process. **3. High-Yield Clinical Pearls for NEET-PG:** * **Black vs. Brown Stones:** * **Black stones** form in the gallbladder and are associated with **hemolysis** and cirrhosis [3]. They are usually radiopaque (visible on X-ray). * **Brown stones** form in the bile ducts and are associated with **infection** (e.g., *E. coli*, *Ascaris lumbricoides*, or *Clonorchis sinensis*) [3]. They are usually radiolucent. * **Enzyme Link:** The enzyme **Beta-glucuronidase** (released by bacteria or damaged hepatocytes) plays a key role in pigment stone formation by deconjugating bilirubin diglucuronide into insoluble free bilirubin [3]. * **Radiopacity:** Approximately 50-75% of pigment stones are radiopaque, whereas only 15-20% of cholesterol stones are radiopaque. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, p. 640. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 403-404. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 882-883.

Question 283: Normal liver histology is seen in which of the following conditions?

A. Gilbert syndrome
B. Rotor syndrome
C. Crigler-Najjar syndrome
D. All of the above (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. All of the above**. The underlying medical concept is that **isolated hyperbilirubinemia** (whether unconjugated or conjugated) caused by genetic defects in bilirubin metabolism typically does not result in structural damage to the liver parenchyma. Therefore, the architecture of the liver remains normal under light microscopy [1]. * **Gilbert Syndrome (Option A):** This is the most common hereditary hyperbilirubinemia, caused by reduced activity of the enzyme **UGT1A1**. It presents as mild, fluctuating unconjugated hyperbilirubinemia, often triggered by stress or fasting. Liver histology is **completely normal** [1]. * **Crigler-Najjar Syndrome (Option C):** This involves a more severe (Type I) or partial (Type II) deficiency of **UGT1A1**. While clinically more serious (especially Type I, which can lead to kernicterus), the liver itself shows **normal histology** because the defect is purely enzymatic [1]. * **Rotor Syndrome (Option B):** This is a rare autosomal recessive condition causing conjugated hyperbilirubinemia due to defects in hepatic storage and uptake (OATP1B1/B3). Unlike Dubin-Johnson syndrome, there is **no pigment accumulation**, and the liver histology is **normal** [1]. **Why Dubin-Johnson is the exception:** In **Dubin-Johnson Syndrome**, while the liver function is technically preserved, the liver histology is **abnormal** due to the presence of coarse, **black-brown pigment** (epinephrine metabolites) in the lysosomes of hepatocytes, giving the liver a characteristic "black" gross appearance [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Normal Histology:** Gilbert, Crigler-Najjar, and Rotor syndromes [1]. * **Black Liver/Pigmented Histology:** Dubin-Johnson syndrome [1]. * **Urinary Coproporphyrin:** In Rotor syndrome, total urinary coproporphyrin is elevated; in Dubin-Johnson, total levels are normal, but >80% is Coproporphyrin I. * **Gilbert Syndrome Trigger:** Often diagnosed when mild jaundice appears after a period of fasting or illness. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 858-860.

Question 284: Fatty change in the liver is associated with the use of which medication?

A. Tetracycline (Correct Answer)
B. Erythromycin
C. Chlorpromazine
D. Acetaminophen

Explanation: **Explanation:** **Tetracycline** is a classic cause of **microvesicular steatosis** (fatty change) in the liver. The underlying mechanism involves the inhibition of mitochondrial beta-oxidation of fatty acids and interference with the synthesis of apoproteins [1], [2]. This leads to the accumulation of triglycerides within small vesicles in the hepatocytes, which do not displace the nucleus. High-dose intravenous tetracycline, particularly in pregnant women, can lead to acute fatty liver of pregnancy-like syndrome, which is a high-yield clinical association [2]. **Analysis of Incorrect Options:** * **Erythromycin:** Primarily associated with **cholestatic jaundice** (specifically Erythromycin estolate), characterized by bile stasis and inflammation, rather than fatty change. * **Chlorpromazine:** A classic cause of **drug-induced cholestasis**. It causes "bland cholestasis" or a sensitivity-type reaction in the bile canaliculi [2]. * **Acetaminophen:** The hallmark of acetaminophen toxicity is **centrilobular (Zone 3) hepatic necrosis**, not fatty change [2]. It is mediated by the toxic metabolite NAPQI when glutathione stores are depleted. **High-Yield Clinical Pearls for NEET-PG:** * **Microvesicular Steatosis:** Remember the mnemonic **"RATS"**: **R**eye’s syndrome, **A**cute fatty liver of pregnancy, **T**etracycline toxicity, and **S**alicylates. * **Macrovesicular Steatosis:** Most commonly caused by **Alcohol**, Obesity, and Diabetes Mellitus [3], [4]. * **Zone 3 Necrosis:** Besides Acetaminophen, it is also seen in Halothane toxicity and Ischemic hepatitis ("Shock liver"). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, p. 73. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 846-847. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, p. 848. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 851-852.

Question 285: Which of the following statements are true about hepatocellular carcinoma?

A. Associated with HBV and HCV (Correct Answer)
B. Cirrhosis is a predisposing factor
C. The fibrolamellar variety is not associated with cirrhosis
D. Has a low propensity for vascular invasion

Explanation: **Explanation:** Hepatocellular Carcinoma (HCC) is the most common primary malignancy of the liver, strongly linked to chronic liver injury and genetic mutations [1]. **1. Why Option A is Correct:** Chronic viral hepatitis is the leading cause of HCC worldwide [4]. **HBV** (a DNA virus) can cause HCC even without cirrhosis by integrating into the host genome and acting as a direct oncogene [3]. **HCV** (an RNA virus) causes HCC primarily through the pathway of chronic inflammation and subsequent cirrhosis [3]. **2. Analysis of Other Options:** * **Option B (Cirrhosis):** While the question asks for the "true" statement, Option B is also technically true in clinical practice (80-90% of HCC cases arise in cirrhotic livers) [1]. However, in many standardized exams, the viral association (A) is prioritized as the primary etiological driver. * **Option C (Fibrolamellar Variant):** This is a distinct subtype of HCC that typically occurs in **young adults (20-40 years)**, has no gender predilection, and is notably **not associated with cirrhosis** or HBV/HCV. It has a better prognosis. * **Option D (Vascular Invasion):** This is incorrect. HCC has a **high propensity for vascular invasion**, particularly into the portal vein and hepatic veins (sometimes extending into the inferior vena cava). **NEET-PG High-Yield Pearls:** * **Tumor Marker:** Alpha-fetoprotein (AFP) is the most common marker (levels >200 ng/mL are highly suggestive) [2]. * **Morphology:** Shows a "trabecular" pattern; bile production by tumor cells is a pathognomonic feature. * **Risk Factors:** Aflatoxin B1 (causes p53 mutation at codon 249), Hemochromatosis, and NAFLD/NASH [1]. * **Radiology:** Characterized by "arterial enhancement" and "venous washout" on contrast CT/MRI. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 876-877. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 399-400. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 336-337. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 215-216.

Question 286: Macro-vesicular fatty liver is seen in which of the following conditions?

A. Protein-Energy malnutrition (Correct Answer)
B. Viral hepatitis
C. Acute fatty liver of Pregnancy
D. Reye's syndrome

Explanation: **Explanation:** The hallmark of **Macro-vesicular steatosis** is the presence of a single, large fat droplet within the hepatocyte that displaces the nucleus to the periphery [1]. This occurs due to an imbalance between the synthesis, utilization, and export of triglycerides. **1. Why Protein-Energy Malnutrition (PEM) is correct:** In conditions like Kwashiorkor, there is a severe deficiency of amino acids required for the synthesis of **Apolipoproteins** (specifically Apo B-100). Since triglycerides must bind to apolipoproteins to form VLDLs for export from the liver, a lack of these proteins leads to the accumulation of fat within hepatocytes, resulting in macro-vesicular steatosis. **2. Analysis of Incorrect Options:** * **Viral Hepatitis:** Typically presents with hepatocyte swelling (ballooning degeneration), Councilman bodies (apoptosis), and inflammatory infiltrates, rather than significant fatty change [3]. * **Acute Fatty Liver of Pregnancy (AFLP) & Reye’s Syndrome:** These are classic examples of **Micro-vesicular steatosis**. In these conditions, the liver is filled with tiny fat droplets that do *not* displace the nucleus. This is usually due to mitochondrial dysfunction (e.g., LCHAD deficiency in AFLP or salicylate use in Reye’s). **High-Yield Clinical Pearls for NEET-PG:** * **Macro-vesicular causes:** Obesity, Diabetes Mellitus, Chronic Alcoholism (most common), and PEM [1], [2]. * **Micro-vesicular causes:** Reye’s Syndrome, AFLP, Valproate toxicity, and Tetracycline toxicity. * **Special Stain:** **Sudan IV** or **Oil Red O** can be used to demonstrate fat on frozen sections (fat is dissolved in routine paraffin processing). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 848-850. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 851-852. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 388-389.

Question 287: What is the most common site of cholangiocarcinoma?

A. Distal biliary tract
B. Hilum (Correct Answer)
C. Intrahepatic duct
D. Multifocal

Explanation: **Explanation:** Cholangiocarcinoma (CCA) is a malignancy arising from the epithelial lining of the biliary tree. It is anatomically classified into three types: Intrahepatic, Perihilar, and Distal. **Why the Hilum is Correct:** The **Perihilar region (Hilum)** is the most common site, accounting for approximately **50% to 60%** of all cases. These tumors, specifically located at the junction of the right and left hepatic ducts, are famously known as **Klatskin tumors**. Their strategic location often leads to early obstructive jaundice. **Analysis of Incorrect Options:** * **Distal Biliary Tract:** This accounts for about **20% to 30%** of cases. These tumors are located between the junction of the cystic duct and the Ampulla of Vater. * **Intrahepatic Duct:** This is the least common site, representing only **10%** of cases. These tumors occur within the liver parenchyma, proximal to the second-order bile ducts. * **Multifocal:** While cholangiocarcinoma can occasionally be multifocal (especially the intrahepatic subtype), it is a pattern of presentation rather than a primary anatomical site. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors:** Primary Sclerosing Cholangitis (most common in the West), *Clonorchis sinensis* (liver fluke) infection, and Choledochal cysts. * **Morphology:** Most are well-to-moderately differentiated **adenocarcinomas** with marked desmoplasia (dense fibrous stroma) [1]. * **Tumor Marker:** **CA 19-9** is frequently elevated (though non-specific). * **Imaging:** Magnetic Resonance Cholangiopancreatography (MRCP) is the gold standard for visualizing the extent of ductal involvement. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 880-881.

Question 288: In a patient with liver cirrhosis, where does portal vein obstruction typically occur?

A. Portal vein
B. Splenic vein
C. Sinusoids (Correct Answer)
D. Hepatic vein

Explanation: **Explanation:** In liver cirrhosis, the primary site of portal hypertension and obstruction is the **sinusoids** [1]. The pathophysiology involves two main mechanisms: 1. **Structural Changes:** Chronic injury leads to the activation of **Hepatic Stellate Cells (Ito cells)**, which transform into myofibroblasts and deposit collagen in the Space of Disse (fibrosis) [2]. This results in "capillarization" of the sinusoids, narrowing the lumen and increasing resistance to blood flow. 2. **Dynamic Changes:** Regenerative nodules physically compress the sinusoids and terminal hepatic veins, further obstructing the intrahepatic portal circulation. **Analysis of Options:** * **Portal Vein (Option A):** Obstruction here is termed **Pre-hepatic** portal hypertension (e.g., Portal Vein Thrombosis) [1]. While it causes portal hypertension, it is not the primary site of resistance *within* a cirrhotic liver. * **Splenic Vein (Option B):** Obstruction here causes **localized portal hypertension** (isolated gastric varices) but is not a feature of generalized cirrhosis. * **Hepatic Vein (Option D):** Obstruction here is termed **Post-hepatic** portal hypertension, characteristic of **Budd-Chiari Syndrome**, not cirrhosis [1]. **NEET-PG High-Yield Pearls:** * **Classification of Portal HTN:** * *Pre-hepatic:* Portal vein thrombosis [1]. * *Intra-hepatic (Presinusoidal):* Schistosomiasis, Sarcoidosis [1]. * *Intra-hepatic (Sinusoidal):* **Cirrhosis (Most common cause) [1].** * *Post-hepatic:* Budd-Chiari, Right-sided heart failure [1]. * **Key Cell:** The **Stellate Cell** is the most important cell involved in hepatic fibrosis [2]. * **Clinical Sign:** The earliest clinical sign of portal hypertension is often **splenomegaly**. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 832-835. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 381-382.

Question 289: What is a known adverse effect of thorium dioxide?

A. Lymphoma
B. Lymphangiosarcoma
C. Angiosarcoma (Correct Answer)
D. Hemangioendothelioma

Explanation: **Explanation:** **Thorium dioxide (Thorotrast)** is a radiopaque contrast medium used historically in the 1930s–1950s [1]. It is a potent carcinogen because it emits alpha particles and has an extremely long biological half-life (several decades), as it is sequestered by the Reticuloendothelial System (RES), primarily in the liver, spleen, and bone marrow [1]. **Why Angiosarcoma is correct:** Angiosarcoma of the liver is a rare, highly aggressive malignant vascular tumor. Thorium dioxide is the classic, high-yield etiologic agent associated with its development, often occurring after a long latent period (20–30 years) [1]. The radioactive particles cause chronic DNA damage to the sinusoidal endothelial cells, leading to malignant transformation. **Why other options are incorrect:** * **Lymphoma:** While radiation can increase the risk of certain hematological malignancies, Thorotrast is specifically linked to solid tumors of the RES organs (liver/spleen) rather than primary lymphomas. * **Lymphangiosarcoma:** This is a malignancy of lymphatic vessels, most commonly associated with chronic lymphedema (Stewart-Treves Syndrome), not radioactive contrast exposure. * **Hemangioendothelioma:** This is a vascular tumor of intermediate malignancy (between a hemangioma and angiosarcoma). While it occurs in the liver, it is not the classic association for Thorotrast. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors for Hepatic Angiosarcoma:** Thorotrast, Vinyl Chloride monomer (PVC industry workers), Arsenic (pesticides/Fowler’s solution), and Anabolic steroids. * **Tumor Marker:** Angiosarcomas are typically positive for **CD31** (PECAM-1) and **CD34**. * **Imaging:** On X-ray, Thorotrast can sometimes be seen as radio-opacities in the liver and spleen decades after administration. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 216-217.

Question 290: Which of the following is NOT a risk factor for cholangiocarcinoma?

A. Primary sclerosing cholangitis
B. Hepatolithiasis
C. Liver flukes
D. Primary biliary cirrhosis (Correct Answer)

Explanation: **Explanation:** Cholangiocarcinoma (CCA) is a malignancy arising from the epithelial lining of the biliary tree [2]. The primary pathophysiology involves **chronic inflammation and cholestasis**, which lead to cellular injury, DNA damage, and malignant transformation. **Why Primary Biliary Cirrhosis (PBC) is the correct answer:** While PBC (now called Primary Biliary Cirrhosis/Cholangitis) involves chronic inflammation of the small intrahepatic bile ducts [3], it is **not** traditionally considered a significant risk factor for cholangiocarcinoma. Instead, PBC is more closely associated with an increased risk of **Hepatocellular Carcinoma (HCC)** once cirrhosis develops. **Analysis of Incorrect Options (Risk Factors for CCA):** * **Primary Sclerosing Cholangitis (PSC):** This is the most common predisposing factor in the Western world. Approximately 10-15% of PSC patients develop CCA [1]. * **Hepatolithiasis (Intrahepatic bile duct stones):** Chronic irritation and recurrent bacterial infections caused by stones lead to chronic proliferative cholangitis, a precursor to malignancy [4]. * **Liver Flukes (*Opisthorchis viverrini* and *Clonorchis sinensis*):** Highly prevalent in Southeast Asia, these parasites reside in the bile ducts, causing chronic inflammation and promoting carcinogenesis. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site:** The confluence of the right and left hepatic ducts (**Klatskin tumor**). * **Tumor Marker:** **CA 19-9** is frequently elevated (though non-specific). * **Congenital Risk Factor:** **Choledochal cysts** (Type I and IV) significantly increase CCA risk due to bile stasis and reflux of pancreatic enzymes. * **Thorotrast:** A historical radiocontrast agent strongly linked to CCA and hepatic angiosarcoma. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 865-866. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 880-881. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 864-865. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, p. 862.

Practice by Chapter

Jaundice and Cholestasis

Practice Questions

Viral Hepatitis

Practice Questions

Alcoholic and Non-alcoholic Fatty Liver Disease

Practice Questions

Drug and Toxin Induced Liver Injury

Practice Questions

Cirrhosis and Its Complications

Practice Questions

Metabolic Liver Diseases

Practice Questions

Liver Tumors

Practice Questions

Gallbladder and Biliary Tract Diseases

Practice Questions

Congenital Liver Diseases

Practice Questions

Liver Transplantation Pathology

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free